ladarixin (DF-2156A)

P2, N=140, Active, not recruiting, Dompé Farmaceutici S.p.A | Trial primary completion date: Apr 2024 --> Mar 2025

Taken together, the allosteric CXCR1/2 inhibitor ladarixin effectively blocks neutrophil recruitment on the level of neutrophil extravasation without affecting firm adhesion. Clinically, this mode of action has interesting therapeutic potential to prevent neutrophil extravasation in inflammatory diseases including inflammatory bowel disease, psoriasis and other neutrophil driven disorders.

It discusses anti-CXCL1 antibodies and CXCR2 antagonists, including AZD5069, SB225002, SCH-479833, navarixin/SCH-527123, ladarixin/DF2156A, and reparixin, as well as strategies to enhance CXCR2 expression in lymphocytes during adoptive cell therapy to improve immunotherapy outcomes. CXCR2 inhibitors are well tolerated by patients in clinical trials. However, the limited number of studies evaluating these agents in combination with standard chemotherapy precludes any definitive conclusions.

Strikingly, even in the absence of an effect on glycemic control, late LDX mitigated STZ-induced mechanical allodynia and thermal hyperalgesia and vitreous (CXCL8, CitH3) and retinal (CXCL8, CXCR1/2, myeloperoxidase, CitH3) inflammatory/pro-angiogenic (vascular endothelial growth factor, CD34) signs of DR. These data confirm the efficacy of LDX in STZ-induced T1DM and provide evidence of a protective effect also against DPN and onset of DR which is independent of its effect on β-cell functionality preservation and glycemic control.

P2, N=140, Active, not recruiting, Dompé Farmaceutici S.p.A | Phase classification: P3 --> P2 | N=327 --> 140 | Trial primary completion date: Mar 2025 --> Apr 2024

Our observations establish iMSCs as major contributors to drug resistance, reveal EVs as physiological triggers of iMSC development and highlight a promising combination strategy to improve therapy response in bone cancer patients.

P1, N=40, Recruiting, NYU Langone Health | Phase classification: P1/2 --> P1

P2, N=0, Withdrawn, NYU Langone Health | N=28 --> 0 | Not yet recruiting --> Withdrawn

P1/2, N=40, Recruiting, NYU Langone Health | Not yet recruiting --> Recruiting | Phase classification: P1 --> P1/2

P2, N=28, Not yet recruiting, NYU Langone Health

P1, N=12, Not yet recruiting, NYU Langone Health

Ladarixin in combination with anti-PD-1 might represent an extremely effective approach for the treatment of immunotherapy refractory PDAC, allowing pro-tumoral to immune-permissive microenvironment conversion.